M&A
Arxada Nears Deal for Enviro Tech at Hefty Multiple
Published: November 30th, 2021
Bain- and Cinven-backed chemicals company Arxada AG is near a deal for Enviro Tech after a Capstone Partners-run auction.
Insights & Analysis
Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.
Page 42
M&A
Drinks With The Deal: Squire Patton Boggs' James Barresi
By David Marcus
|
Published: November 18th, 2021
James Barresi, who heads the firm's financial services practice, explains how his time as an in-house lawyer at US Bancorp in the 1990s has shaped his approach to private practice and how he works with clients considering a deal.
M&A
Book Review: Consider the Cocktail
By David Marcus
|
Published: November 4th, 2021
The new 'Oxford Companion to Spirits & Cocktails' treats the beverages in all of their aspects from production to history to brand management.
Podcasts
Drinks With The Deal: Spirits Experts David Wondrich and Noah Rothbaum
By David Marcus
|
Published: November 4th, 2021
David Wondrich and Noah Rothbaum discuss their work editing the new 'Oxford Companion to Spirits & Cocktails,' which considers at length the companies, entrepreneurs and trends that have driven the alcohol business.
Podcasts
Drinks With The Deal: Edward Zimmerman of Lowenstein Sandler
By David Marcus
|
Published: October 28th, 2021
Ed Zimmerman discusses building the tech group at Lowenstein Sandler and his commitment to social justice.
Podcasts
Fresh Start: Professor Melissa Jacoby
By Stephanie Gleason
|
Published: October 25th, 2021
The University of North Carolina at Chapel Hill professor discusses finding the boundaries of bankruptcy in Purdue and more on the latest episode of Fresh Start.
M&A
Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss
By David Marcus
|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.
M&A
OpEd: ESG in Due Diligence Is Not Just Another Box to Check
By Deal Contributors
|
Published: October 5th, 2021
With ESG now a day-to-day focus for management and directors across industries, companies would be well-served to undertake a thoughtful assessment of ESG risks when evaluating potential targets in M&A activities.
Activism
CorpGov: Barshay Says Lina Khan Can't Sue Everybody
By Tom Terrarosa
|
Published: October 1st, 2021
The powerhouse corporate attorney handed out some advice to companies, ESG investors and the broader investment community at The Deal's Corporate Governance 2021 conference.
